Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	209	jackowski-g$.in.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:12
L2	92	thatcher-b$.in.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:12
L3	1774	marshall-j$.in.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:12
L4	78	yantha-j$.in.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:12
L5	78	vrees-t$.in.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:20
L6	1861	L1 OR L2 OR L3 OR L4 OR L5 AND ((cardiovascular ADJ disease) OR (myocardial ADJ infarction))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:14
L7	1861	L1 OR L2 OR L3 OR L4 OR L5 AND ((cardiovascular ADJ disease) OR (myocardial ADJ infarction)).ab.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:15
L8	11960	((cardiovascular ADJ disease)OR(myocardial ADJ infarction)).ab.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:14
L9	1861	L1 OR L2 OR L3 OR L4 OR L5 AND ((cardiovascular ADJ disease) OR (myocardial ADJ infarction)).ab. AND marker.ab.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:15
L10	2	WO-9614580-$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:45

L11	10	"5827659"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:44
L12	7	"5817768"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:44
L13	95	"5538897"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:44
L14	0	WO-0009562-$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:45
L15	1	WO-200009562-$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:45
L16	1	WO-200105422-$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:45
L17	1	WO-200049410-$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:46
L18	1	WO-200175454-$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:46
L19	0	WO-199807036-$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:46
L20	2	WO-9807036-$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:46

L21	2	WO-9014148-$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:47
L22	2	WO-9324834-$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:47
L23	90	"6020208"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:47
L24	88	"5062935"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:49
L25	1720	530/300,326,350.ccls. AND (myocardial ADJ infarction)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 12:08
L26	2	wo-9636986-$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 12:12
L27	2	wo-9942119-$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 12:12

NCBI PubMed National Library of Medicine NLM

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Boo

Search PubMed for Preview Go Clear

Limits **Preview/Index** History Clipboard Details

- Enter terms and click Preview to see only the number of search results.
- To combine searches use # before search number, e.g., (#2 OR #3) AND asthma.
- Click on query # to add to strategy

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Search	Most Recent Queries	Time	Result
#17	**Related Articles** for **PubMed** (Select **14989564**)	11:53:28	549
#16	Search **fibrinogen AND myocardial infarction AND (marker OR biomarker)**	11:53:18	295
#15	Search **myocardial infarction AND (marker OR biomarker)**	11:52:49	4324

Add Term(s) to Query or View Index:

- Enter a term in the text box; use the pull-down menu to specify a search field.
- Click Preview to add terms to the query box and see the number of search results, or click Index to view terms within a field.

All Fields Preview Index

Click AND OR NOT to add a term to the query box.

h cb hg e e e fcg e b e

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653aud

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

---

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS	4	OCT 28	KOREAPAT now available on STN
NEWS	5	NOV 30	PHAR reloaded with additional data
NEWS	6	DEC 01	LISA now available on STN
NEWS	7	DEC 09	12 databases to be removed from STN on December 31, 2004
NEWS	8	DEC 15	MEDLINE update schedule for December 2004
NEWS	9	DEC 17	ELCOM reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	10	DEC 17	COMPUAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	11	DEC 17	SOLIDSTATE reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	12	DEC 17	CERAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	13	DEC 17	THREE NEW FIELDS ADDED TO IFIPAT/IFIUDB/IFICDB
NEWS	14	DEC 30	EPFULL: New patent full text database to be available on STN
NEWS	15	DEC 30	CAPLUS - PATENT COVERAGE EXPANDED
NEWS	16	JAN 03	No connect-hour charges in EPFULL during January and February 2005
NEWS	17	JAN 11	CA/CAPLUS - Expanded patent coverage to include Russia (Federal Institute of Industrial Property)

NEWS EXPRESS	JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:22:08 ON 21 JAN 2005

```
=> file registry
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'REGISTRY' ENTERED AT 12:22:30 ON 21 JAN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   19 JAN 2005  HIGHEST RN 817158-90-0
DICTIONARY FILE UPDATES:  19 JAN 2005  HIGHEST RN 817158-90-0

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> s fibrinogen
          1024 FIBRINOGEN
             6 FIBRINOGENS
L1        1029 FIBRINOGEN
                (FIBRINOGEN OR FIBRINOGENS)

=> index bioscience medicine
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         5.03       5.24

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
       AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS,
       BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB,
       CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 12:23:04 ON 21 JAN 2005

78 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s fibrinogen
       2029   FILE ADISCTI
        138   FILE ADISINSIGHT
        268   FILE ADISNEWS
        502   FILE AGRICOLA
        161   FILE ANABSTR
         57   FILE ANTE
          4   FILE AQUALINE
        105   FILE AQUASCI
        450   FILE BIOBUSINESS
        118   FILE BIOCOMMERCE
        515   FILE BIOENG
```

```
    31334   FILE BIOSIS
      576   FILE BIOTECHABS
      576   FILE BIOTECHDS
     6481   FILE BIOTECHNO
     2010   FILE CABA
     3587   FILE CANCERLIT
    30223   FILE CAPLUS
      115   FILE CEABA-VTB
        5   FILE CEN
       92   FILE CIN
      695   FILE CONFSCI
       11   FILE CROPU
     1921   FILE DDFB
     5797   FILE DDFU
     5877   FILE DGENE
      719   FILE DISSABS
     1921   FILE DRUGB
       99   FILE DRUGMONOG2
     8235   FILE DRUGU
      194   FILE EMBAL
    34408   FILE EMBASE
     5465   FILE ESBIOBASE
      305   FILE FEDRIP
      164   FILE FROSTI
38 FILES SEARCHED...
      134   FILE FSTA
     4405   FILE GENBANK
       44   FILE HEALSAFE
     2002   FILE IFIPAT
       48   FILE IMSDRUGNEWS
       58   FILE IMSPRODUCT
       61   FILE IMSRESEARCH
     3834   FILE JICST-EPLUS
        3   FILE KOSMET
     2542   FILE LIFESCI
       17   FILE MEDICONF
    37491   FILE MEDLINE
      164   FILE NIOSHTIC
      354   FILE NTIS
        4   FILE NUTRACEUT
       15   FILE OCEAN
     9706   FILE PASCAL
      281   FILE PHAR
       41   FILE PHARMAML
        1   FILE PHIC
      279   FILE PHIN
      677   FILE PROMT
     1752   FILE PROUSDDR
        1   FILE PS
        2   FILE RDISCLOSURE
64 FILES SEARCHED...
    22169   FILE SCISEARCH
       17   FILE SYNTHLINE
    12419   FILE TOXCENTER
    11170   FILE USPATFULL
      755   FILE USPAT2
       27   FILE VETB
      174   FILE VETU
        3   FILE WATER
     2425   FILE WPIDS
       18   FILE WPIFV
     2425   FILE WPINDEX
      408   FILE IPA
```

```
        86   FILE NAPRALERT
       573   FILE NLDB

  74 FILES HAVE ONE OR MORE ANSWERS,   78 FILES SEARCHED IN STNINDEX

L2   QUE FIBRINOGEN

=> d rank
F1       37491   MEDLINE
F2       34408   EMBASE
F3       31334   BIOSIS
F4       30223   CAPLUS
F5       22169   SCISEARCH
F6       12419   TOXCENTER
F7       11170   USPATFULL
F8        9706   PASCAL
F9        8235   DRUGU
F10       6481   BIOTECHNO
F11       5877   DGENE
F12       5797   DDFU
F13       5465   ESBIOBASE
F14       4405   GENBANK
F15       3834   JICST-EPLUS
F16       3587   CANCERLIT
F17       2542   LIFESCI
F18       2425   WPIDS
F19       2425   WPINDEX
F20       2029   ADISCTI
F21       2010   CABA
F22       2002   IFIPAT
F23       1921   DDFB
F24       1921   DRUGB
F25       1752   PROUSDDR
F26        755   USPAT2
F27        719   DISSABS
F28        695   CONFSCI
F29        677   PROMT
F30        576   BIOTECHABS
F31        576   BIOTECHDS
F32        573   NLDB
F33        515   BIOENG
F34        502   AGRICOLA
F35        450   BIOBUSINESS
F36        408   IPA
F37        354   NTIS
F38        305   FEDRIP
F39        281   PHAR
F40        279   PHIN
F41        268   ADISNEWS
F42        194   EMBAL
F43        174   VETU
F44        164   FROSTI
F45        164   NIOSHTIC
F46        161   ANABSTR
F47        138   ADISINSIGHT
F48        134   FSTA
F49        118   BIOCOMMERCE
F50        115   CEABA-VTB
F51        105   AQUASCI
F52         99   DRUGMONOG2
F53         92   CIN
F54         86   NAPRALERT
F55         61   IMSRESEARCH
```

```
F56          58   IMSPRODUCT
F57          57   ANTE
F58          48   IMSDRUGNEWS
F59          44   HEALSAFE
F60          41   PHARMAML
F61          27   VETB
F62          18   WPIFV
F63          17   MEDICONF
F64          17   SYNTHLINE
F65          15   OCEAN
F66          11   CROPU
F67           5   CEN
F68           4   AQUALINE
F69           4   NUTRACEUT
F70           3   KOSMET
F71           3   WATER
F72           2   RDISCLOSURE
F73           1   PHIC
F74           1   PS


=> file f1, f2, f3, f4, f5, f6, f7, f8, f9, f10
COST IN U.S. DOLLARS                        SINCE FILE      TOTAL
                                               ENTRY    SESSION
FULL ESTIMATED COST                             2.95       8.19

FILE 'MEDLINE' ENTERED AT 12:25:57 ON 21 JAN 2005

FILE 'EMBASE' ENTERED AT 12:25:57 ON 21 JAN 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'BIOSIS' ENTERED AT 12:25:57 ON 21 JAN 2005
Copyright (c) 2005 The Thomson Corporation.

FILE 'CAPLUS' ENTERED AT 12:25:57 ON 21 JAN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'SCISEARCH' ENTERED AT 12:25:57 ON 21 JAN 2005
Copyright (c) 2005 The Thomson Corporation.

FILE 'TOXCENTER' ENTERED AT 12:25:57 ON 21 JAN 2005
COPYRIGHT (C) 2005 ACS

FILE 'USPATFULL' ENTERED AT 12:25:57 ON 21 JAN 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PASCAL' ENTERED AT 12:25:57 ON 21 JAN 2005
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2005 INIST-CNRS. All rights reserved.

FILE 'DRUGU' ENTERED AT 12:25:57 ON 21 JAN 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'BIOTECHNO' ENTERED AT 12:25:57 ON 21 JAN 2005
COPYRIGHT (C) 2005 Elsevier Science B.V., Amsterdam. All rights reserved.

=> s fibrinogen
L3      203636 FIBRINOGEN
```

```
=> s myocardial infarction
L4      473386 MYOCARDIAL INFARCTION

=> s myocardial (w) infarction
L5      473386 MYOCARDIAL (W) INFARCTION

=> s (marker OR (biomarker)) AND L3 AND L5
L6        2525 (MARKER OR (BIOMARKER)) AND L3 AND L5

=> dup rem l6
PROCESSING IS APPROXIMATELY  49% COMPLETE FOR L6
PROCESSING IS APPROXIMATELY  86% COMPLETE FOR L6
PROCESSING COMPLETED FOR L6
L7         1897 DUP REM L6 (628 DUPLICATES REMOVED)

=> s jackowski,g?/au
L8         670 JACKOWSKI,G?/AU

=> s thatcher,b?/au
L9         237 THATCHER,B?/AU

=> s marshall,j?/au
L10      19338 MARSHALL,J?/AU

=> s yantha,j?/au
L11         90 YANTHA,J?/AU

=> s vrees,t?/au
L12         87 VREES,T?/AU

=> s L8 OR L9 OR L10 OR L11 OR L12
L13      19980 L8 OR L9 OR L10 OR L11 OR L12

=> dup rem l13
PROCESSING IS APPROXIMATELY   6% COMPLETE FOR L13
PROCESSING IS APPROXIMATELY  12% COMPLETE FOR L13
PROCESSING IS APPROXIMATELY  21% COMPLETE FOR L13
PROCESSING IS APPROXIMATELY  27% COMPLETE FOR L13
PROCESSING IS APPROXIMATELY  34% COMPLETE FOR L13
PROCESSING IS APPROXIMATELY  41% COMPLETE FOR L13
PROCESSING IS APPROXIMATELY  46% COMPLETE FOR L13
PROCESSING IS APPROXIMATELY  54% COMPLETE FOR L13
PROCESSING IS APPROXIMATELY  60% COMPLETE FOR L13
PROCESSING IS APPROXIMATELY  71% COMPLETE FOR L13
PROCESSING IS APPROXIMATELY  76% COMPLETE FOR L13
PROCESSING IS APPROXIMATELY  83% COMPLETE FOR L13
PROCESSING IS APPROXIMATELY  95% COMPLETE FOR L13
PROCESSING COMPLETED FOR L13
L14        9671 DUP REM L13 (10309 DUPLICATES REMOVED)

=> d his

     (FILE 'HOME' ENTERED AT 12:22:08 ON 21 JAN 2005)

     FILE 'REGISTRY' ENTERED AT 12:22:30 ON 21 JAN 2005
L1         1029 S FIBRINOGEN

     INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
     AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS,
     BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB,
     CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 12:23:04 ON 21 JAN 2005
               SEA FIBRINOGEN
              ---------
```

```
 2029   FILE ADISCTI
  138   FILE ADISINSIGHT
  268   FILE ADISNEWS
  502   FILE AGRICOLA
  161   FILE ANABSTR
   57   FILE ANTE
    4   FILE AQUALINE
  105   FILE AQUASCI
  450   FILE BIOBUSINESS
  118   FILE BIOCOMMERCE
  515   FILE BIOENG
31334   FILE BIOSIS
  576   FILE BIOTECHABS
  576   FILE BIOTECHDS
 6481   FILE BIOTECHNO
 2010   FILE CABA
 3587   FILE CANCERLIT
30223   FILE CAPLUS
  115   FILE CEABA-VTB
    5   FILE CEN
   92   FILE CIN
  695   FILE CONFSCI
   11   FILE CROPU
 1921   FILE DDFB
 5797   FILE DDFU
 5877   FILE DGENE
  719   FILE DISSABS
 1921   FILE DRUGB
   99   FILE DRUGMONOG2
 8235   FILE DRUGU
  194   FILE EMBAL
34408   FILE EMBASE
 5465   FILE ESBIOBASE
  305   FILE FEDRIP
  164   FILE FROSTI
  134   FILE FSTA
 4405   FILE GENBANK
   44   FILE HEALSAFE
 2002   FILE IFIPAT
   48   FILE IMSDRUGNEWS
   58   FILE IMSPRODUCT
   61   FILE IMSRESEARCH
 3834   FILE JICST-EPLUS
    3   FILE KOSMET
 2542   FILE LIFESCI
   17   FILE MEDICONF
37491   FILE MEDLINE
  164   FILE NIOSHTIC
  354   FILE NTIS
    4   FILE NUTRACEUT
   15   FILE OCEAN
 9706   FILE PASCAL
  281   FILE PHAR
   41   FILE PHARMAML
    1   FILE PHIC
  279   FILE PHIN
  677   FILE PROMT
 1752   FILE PROUSDDR
    1   FILE PS
    2   FILE RDISCLOSURE
22169   FILE SCISEARCH
   17   FILE SYNTHLINE
12419   FILE TOXCENTER
```

```
          11170   FILE USPATFULL
            755   FILE USPAT2
             27   FILE VETB
            174   FILE VETU
              3   FILE WATER
           2425   FILE WPIDS
             18   FILE WPIFV
           2425   FILE WPINDEX
            408   FILE IPA
             86   FILE NAPRALERT
            573   FILE NLDB
---------L2-----------QUE FIBRINOGEN-----------------------------------------------------------
              ---------

     FILE 'MEDLINE, EMBASE, BIOSIS, CAPLUS, SCISEARCH, TOXCENTER, USPATFULL,
     PASCAL, DRUGU, BIOTECHNO' ENTERED AT 12:25:57 ON 21 JAN 2005
L3        203636 S FIBRINOGEN
L4        473386 S MYOCARDIAL INFARCTION
L5        473386 S MYOCARDIAL (W) INFARCTION
L6          2525 S (MARKER OR (BIOMARKER)) AND L3 AND L5
L7          1897 DUP REM L6 (628 DUPLICATES REMOVED)
L8           670 S JACKOWSKI,G?/AU
L9           237 S THATCHER,B?/AU
L10        19338 S MARSHALL,J?/AU
L11           90 S YANTHA,J?/AU
L12           87 S VREES,T?/AU
L13        19980 S L8 OR L9 OR L10 OR L11 OR L12
L14         9671 DUP REM L13 (10309 DUPLICATES REMOVED)

=> s L7 NOT L14
   7 FILES SEARCHED...
L15        1889 L7 NOT L14

=> s L7 AND L14
   7 FILES SEARCHED...
L16           8 L7 AND L14

=> d his

     (FILE 'HOME' ENTERED AT 12:22:08 ON 21 JAN 2005)

     FILE 'REGISTRY' ENTERED AT 12:22:30 ON 21 JAN 2005
L1          1029 S FIBRINOGEN

     INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
     AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS,
     BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB,
     CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 12:23:04 ON 21 JAN 2005
               SEA FIBRINOGEN
              ---------
            2029   FILE ADISCTI
             138   FILE ADISINSIGHT
             268   FILE ADISNEWS
             502   FILE AGRICOLA
             161   FILE ANABSTR
              57   FILE ANTE
               4   FILE AQUALINE
             105   FILE AQUASCI
             450   FILE BIOBUSINESS
             118   FILE BIOCOMMERCE
             515   FILE BIOENG
           31334   FILE BIOSIS
             576   FILE BIOTECHABS
```

```
   576   FILE BIOTECHDS
  6481   FILE BIOTECHNO
  2010   FILE CABA
  3587   FILE CANCERLIT
 30223   FILE CAPLUS
   115   FILE CEABA-VTB
     5   FILE CEN
    92   FILE CIN
   695   FILE CONFSCI
    11   FILE CROPU
  1921   FILE DDFB
  5797   FILE DDFU
  5877   FILE DGENE
   719   FILE DISSABS
  1921   FILE DRUGB
    99   FILE DRUGMONOG2
  8235   FILE DRUGU
   194   FILE EMBAL
 34408   FILE EMBASE
  5465   FILE ESBIOBASE
   305   FILE FEDRIP
   164   FILE FROSTI
   134   FILE FSTA
  4405   FILE GENBANK
    44   FILE HEALSAFE
  2002   FILE IFIPAT
    48   FILE IMSDRUGNEWS
    58   FILE IMSPRODUCT
    61   FILE IMSRESEARCH
  3834   FILE JICST-EPLUS
     3   FILE KOSMET
  2542   FILE LIFESCI
    17   FILE MEDICONF
 37491   FILE MEDLINE
   164   FILE NIOSHTIC
   354   FILE NTIS
     4   FILE NUTRACEUT
    15   FILE OCEAN
  9706   FILE PASCAL
   281   FILE PHAR
    41   FILE PHARMAML
     1   FILE PHIC
   279   FILE PHIN
   677   FILE PROMT
  1752   FILE PROUSDDR
     1   FILE PS
     2   FILE RDISCLOSURE
 22169   FILE SCISEARCH
    17   FILE SYNTHLINE
 12419   FILE TOXCENTER
 11170   FILE USPATFULL
   755   FILE USPAT2
    27   FILE VETB
   174   FILE VETU
     3   FILE WATER
  2425   FILE WPIDS
    18   FILE WPIFV
  2425   FILE WPINDEX
   408   FILE IPA
    86   FILE NAPRALERT
   573   FILE NLDB
L2          QUE FIBRINOGEN
            ---------
```

FILE 'MEDLINE, EMBASE, BIOSIS, CAPLUS, SCISEARCH, TOXCENTER, USPATFULL, PASCAL, DRUGU, BIOTECHNO' ENTERED AT 12:25:57 ON 21 JAN 2005

L3 203636 S FIBRINOGEN
L4 473386 S MYOCARDIAL INFARCTION
L5 473386 S MYOCARDIAL (W) INFARCTION
L6 2525 S (MARKER OR (BIOMARKER)) AND L3 AND L5
L7 1897 DUP REM L6 (628 DUPLICATES REMOVED)
L8 670 S JACKOWSKI,G?/AU
L9 237 S THATCHER,B?/AU
L10 19338 S MARSHALL,J?/AU
L11 90 S YANTHA,J?/AU
L12 87 S VREES,T?/AU
L13 19980 S L8 OR L9 OR L10 OR L11 OR L12
L14 9671 DUP REM L13 (10309 DUPLICATES REMOVED)
L15 1889 S L7 NOT L14
L16 8 S L7 AND L14

=> d l16 ibib ti abs 1-8

L16 ANSWER 1 OF 8 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN
ACCESSION NUMBER: 2003:54591 BIOSIS
DOCUMENT NUMBER: PREV200300054591
TITLE: Post-translational modification of serum proteins underlies the mass spectral fingerprinting of disease.
AUTHOR(S): **Marshall, John** [Reprint Author]; Kupchak, Peter [Reprint Author]; Zhu, Weimin [Reprint Author]; **Yantha, Jason** [Reprint Author]; **Vrees, Tammy** [Reprint Author]; Furesz, Shirley [Reprint Author]; Jacks, Kelly [Reprint Author]; Smith, Chris [Reprint Author]; Kireeva, Inga [Reprint Author]; Zhang, Rulin [Reprint Author]; Takahashi, Miyoko [Reprint Author]; Stanton, Eric [Reprint Author]; **Jackowski, George** [Reprint Author]
CORPORATE SOURCE: Synx Pharma, 1 Marmac Drive, Toronto, Ontario, M9W 1E7, Canada
SOURCE: Molecular & Cellular Proteomics, (September 2002) Vol. 1, No. 9, pp. 683. print.
Meeting Info.: First World Congress of the Human Proteome Organisation. Versailles, Paris, France. November 21-24, 2002. Human Proteome Organisation.
ISSN: 1535-9476 (ISSN print).
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 22 Jan 2003
Last Updated on STN: 22 Jan 2003
TI Post-translational modification of serum proteins underlies the mass spectral fingerprinting of disease.

L16 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:833556 CAPLUS
DOCUMENT NUMBER: 137:334916
TITLE: Alpha **fibrinogen** biopolymer **marker** indicative of **myocardial infarction** having a molecular weight of 1020 daltons
INVENTOR(S): **Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason; Vrees, Tammy**
PATENT ASSIGNEE(S): Can.
SOURCE: U.S. Pat. Appl. Publ., 10 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002161188	A1	20021031	US 2001-846350	20010430
US 6599877	B2	20030729		
WO 2002088728	A2	20021107	WO 2002-CA619	20020429
WO 2002088728	A3	20021227		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-846350 A 20010430

TI Alpha **fibrinogen** biopolymer **marker** indicative of **myocardial infarction** having a molecular weight of 1020 daltons

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific **marker** identified by the sequence DFLAEGGGVR and characterized as a α **fibrinogen** having a mol. weight of 1020 daltons was found. This **marker** is indicative of **myocardial infarction**.

L16 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:833425 CAPLUS
DOCUMENT NUMBER: 137:334901
TITLE: Alpha **fibrinogen** biopolymer **marker** indicative of **myocardial infarction** or renal failure having a molecular weight of 1350 daltons
INVENTOR(S): **Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason; Vrees, Tammy**
PATENT ASSIGNEE(S): Can.
SOURCE: U.S. Pat. Appl. Publ., 10 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002160528	A1	20021031	US 2001-845729	20010430
WO 2002088722	A2	20021107	WO 2002-CA610	20020426
WO 2002088722	A3	20021227		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-845729 A 20010430

TI Alpha **fibrinogen** biopolymer **marker** indicative of **myocardial infarction** or renal failure having a molecular weight of 1350 daltons

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific **marker** identified by the sequence SESDFLAEGGGVR and characterized as a α **fibrinogen** having a mol. weight of 1350 daltons was found. This **marker** is indicative of **myocardial infarction** or renal failure.

L16 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:833398 CAPLUS
DOCUMENT NUMBER: 137:334899
TITLE: Alpha **fibrinogen** biopolymer **marker** indicative of **myocardial infarction** having a molecular weight of 1536 daltons
INVENTOR(S): **Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason; Vrees, Tammy**
PATENT ASSIGNEE(S): Can.
SOURCE: U.S. Pat. Appl. Publ., 10 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002160423	A1	20021031	US 2001-846780	20010430
WO 2002088718	A2	20021107	WO 2002-CA579	20020425
WO 2002088718	A3	20021227		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-846780 A 20010430

TI Alpha **fibrinogen** biopolymer **marker** indicative of **myocardial infarction** having a molecular weight of 1536 daltons

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection

procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific **marker** identified by the sequence ADSGEGDFLAEGGGVR and characterized as a α **fibrinogen** having a mol. weight of 1536 daltons was found. This **marker** is indicative of **myocardial infarction.**

L16 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:833397 CAPLUS
DOCUMENT NUMBER: 137:334898
TITLE: Alpha **fibrinogen** biopolymer **marker** indicative of **myocardial infarction** having a molecular weight of 1077 daltons
INVENTOR(S): **Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason; Vrees, Tammy**
PATENT ASSIGNEE(S): Can.
SOURCE: U.S. Pat. Appl. Publ., 10 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002160422	A1	20021031	US 2001-846342	20010430
WO 2002088708	A2	20021107	WO 2002-CA620	20020429
WO 2002088708	A3	20031023		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-846342 A 20010430

TI Alpha **fibrinogen** biopolymer **marker** indicative of **myocardial infarction** having a molecular weight of 1077 daltons

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific **marker** identified by the sequence GDFLAEGGGVR and characterized as a α **fibrinogen** having a mol. weight of 1077 daltons was found. This **marker** is indicative of **myocardial infarction.**

L16 ANSWER 6 OF 8 USPATFULL on STN
ACCESSION NUMBER: 2004:255419 USPATFULL
TITLE: Biopolymer **marker** indicative of disease state having a molecular weight of 1518 daltons
INVENTOR(S): **Jackowski, George**, Kettleby, CANADA
Thatcher, Brad, Toronto, CANADA
Marshall, John, Toronto, CANADA
Yantha, Jason, Toronto, CANADA
Vrees, Tammy, Oakville, CANADA

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004198950	A1	20041007	
APPLICATION INFO.:	US 2001-845765	A1	20010430	(9)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MCHALE & SLAVIN, P.A., 2855 PGA BLVD, PALM BEACH GARDENS, FL, 33410
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 696
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
TI Biopolymer **marker** indicative of disease state having a molecular weight of 1518 daltons
AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 7 OF 8 USPATFULL on STN
ACCESSION NUMBER: 2003:4263 USPATFULL
TITLE: Biopolymer **marker** indicative of disease state having a molecular weight of 1211 daltons
INVENTOR(S): **Jackowski, George**, Kettleby, CANADA
Thatcher, Brad, Toronto, CANADA
Marshall, John, Toronto, CANADA
Yantha, Jason, Toronto, CANADA
Vrees, Tammy, Oakville, CANADA

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003004307	A1	20030102	
APPLICATION INFO.:	US 2001-845731	A1	20010430	(9)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MCHALE & SLAVIN, 4440 PGA BLVD, SUITE 402, PALM BEACH GARDENS, FL, 33410
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 700
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
TI Biopolymer **marker** indicative of disease state having a molecular weight of 1211 daltons

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 8 OF 8 USPATFULL on STN

ACCESSION NUMBER:	2002:301729 USPATFULL			
TITLE:	Biopolymer **marker** indicative of disease state having a molecular weight of 1690 daltons			
INVENTOR(S):	**Jackowski, George,** Kettleby, CANADA **Thatcher, Brad,** Toronto, CANADA **Marshall, John,** Toronto, CANADA **Yantha, Jason,** Toronto, CANADA **Vrees, Tammy,** Oakville, CANADA			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002169278	A1	20021114	
	US 6593298	B2	20030715	
APPLICATION INFO.:	US 2001-845730	A1	20010430	(9)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	MCHALE & SLAVIN, 4440 PGA BLVD, SUITE 402, PALM BEACH GARDENS, FL, 33410			
NUMBER OF CLAIMS:	2			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	4 Drawing Page(s)			
LINE COUNT:	699			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Biopolymer **marker** indicative of disease state having a molecular weight of 1690 daltons

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 12:22:08 ON 21 JAN 2005)

FILE 'REGISTRY' ENTERED AT 12:22:30 ON 21 JAN 2005
L1 1029 S FIBRINOGEN

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 12:23:04 ON 21 JAN 2005
SEA FIBRINOGEN

```
---------
 2029   FILE ADISCTI
  138   FILE ADISINSIGHT
  268   FILE ADISNEWS
  502   FILE AGRICOLA
  161   FILE ANABSTR
   57   FILE ANTE
    4   FILE AQUALINE
  105   FILE AQUASCI
  450   FILE BIOBUSINESS
  118   FILE BIOCOMMERCE
  515   FILE BIOENG
31334   FILE BIOSIS
  576   FILE BIOTECHABS
  576   FILE BIOTECHDS
 6481   FILE BIOTECHNO
 2010   FILE CABA
 3587   FILE CANCERLIT
30223   FILE CAPLUS
  115   FILE CEABA-VTB
    5   FILE CEN
   92   FILE CIN
  695   FILE CONFSCI
   11   FILE CROPU
 1921   FILE DDFB
 5797   FILE DDFU
 5877   FILE DGENE
  719   FILE DISSABS
 1921   FILE DRUGB
   99   FILE DRUGMONOG2
 8235   FILE DRUGU
  194   FILE EMBAL
34408   FILE EMBASE
 5465   FILE ESBIOBASE
  305   FILE FEDRIP
  164   FILE FROSTI
  134   FILE FSTA
 4405   FILE GENBANK
   44   FILE HEALSAFE
 2002   FILE IFIPAT
   48   FILE IMSDRUGNEWS
   58   FILE IMSPRODUCT
   61   FILE IMSRESEARCH
 3834   FILE JICST-EPLUS
    3   FILE KOSMET
 2542   FILE LIFESCI
   17   FILE MEDICONF
37491   FILE MEDLINE
  164   FILE NIOSHTIC
  354   FILE NTIS
    4   FILE NUTRACEUT
   15   FILE OCEAN
 9706   FILE PASCAL
  281   FILE PHAR
   41   FILE PHARMAML
    1   FILE PHIC
  279   FILE PHIN
  677   FILE PROMT
 1752   FILE PROUSDDR
    1   FILE PS
    2   FILE RDISCLOSURE
22169   FILE SCISEARCH
   17   FILE SYNTHLINE
```

```
            12419   FILE TOXCENTER
            11170   FILE USPATFULL
              755   FILE USPAT2
               27   FILE VETB
              174   FILE VETU
                3   FILE WATER
             2425   FILE WPIDS
               18   FILE WPIFV
             2425   FILE WPINDEX
              408   FILE IPA
               86   FILE NAPRALERT
              573   FILE NLDB
L2               QUE FIBRINOGEN
                 ---------

     FILE 'MEDLINE, EMBASE, BIOSIS, CAPLUS, SCISEARCH, TOXCENTER, USPATFULL,
     PASCAL, DRUGU, BIOTECHNO' ENTERED AT 12:25:57 ON 21 JAN 2005
L3          203636 S FIBRINOGEN
L4          473386 S MYOCARDIAL INFARCTION
L5          473386 S MYOCARDIAL (W) INFARCTION
L6            2525 S (MARKER OR (BIOMARKER)) AND L3 AND L5
L7            1897 DUP REM L6 (628 DUPLICATES REMOVED)
L8             670 S JACKOWSKI,G?/AU
L9             237 S THATCHER,B?/AU
L10          19338 S MARSHALL,J?/AU
L11             90 S YANTHA,J?/AU
L12             87 S VREES,T?/AU
L13          19980 S L8 OR L9 OR L10 OR L11 OR L12
L14           9671 DUP REM L13 (10309 DUPLICATES REMOVED)
L15           1889 S L7 NOT L14
L16              8 S L7 AND L14

=> s MALDI
L17         37915 MALDI

=> s L17 AND L7
L18            55 L17 AND L7

=> s L18 NOT L14
L19            52 L18 NOT L14

=> dup rem l19
PROCESSING COMPLETED FOR L19
L20            52 DUP REM L19 (0 DUPLICATES REMOVED)

=> d l20 ibib ti abs 40-52

L20  ANSWER 40 OF 52  USPATFULL on STN
ACCESSION NUMBER:       2002:287670  USPATFULL
TITLE:                  Biopolymer marker indicative of disease state
                        having a molecular of weight of 1525 daltons
INVENTOR(S):            Jackowski, George, Kettleby, CANADA
                        Thatcher, Brad, Toronto, CANADA
                        Marshall, John, Toronto, CANADA
                        Yantha, Jason, Toronto, CANADA
                        Vrees, Tammy, Oakville, CANADA

                             NUMBER        KIND    DATE
                        ---------------- ------ --------
PATENT INFORMATION:     US 2002160533      A1   20021031
APPLICATION INFO.:      US 2001-846779     A1   20010430  (9)
DOCUMENT TYPE:          Utility
FILE SEGMENT:           APPLICATION
```

LEGAL REPRESENTATIVE: MCHALE & SLAVIN, 4440 PGA BLVD, SUITE 402, PALM BEACH GARDENS, FL, 33410
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 697
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
TI Biopolymer **marker** indicative of disease state having a molecular of weight of 1525 daltons
AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 41 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2002:287666 USPATFULL
TITLE: Biopolymer **marker** indicative of disease state having a molecular weight of 1562 daltons
INVENTOR(S): Jackowski, George, Kettleby, CANADA
Thatcher, Brad, Toronto, CANADA
Vrees, Tammy, Oakville, CANADA
Yantha, Jason, Toronto, CANADA
Marshall, John, Toronto, CANADA

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002160529	A1	20021031	
APPLICATION INFO.:	US 2001-845738	A1	20010430	(9)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MCHALE & SLAVIN, 4440 PGA BLVD, SUITE 402, PALM BEACH GARDENS, FL, 33410
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 699
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
TI Biopolymer **marker** indicative of disease state having a molecular weight of 1562 daltons
AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 42 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2002:287571 USPATFULL
TITLE: Biopolymer **marker** indicative of disease state having a molecular weight of 1777 daltons
INVENTOR(S): Jackowski, George, Kettleby, CANADA

Thatcher, Brad, Toronto, CANADA
Marshall, John, Toronto, CANADA
Yantha, Jason, Toronto, CANADA
Vrees, Tammy, Oakville, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002160434	A1	20021031
APPLICATION INFO.:	US 2001-845735	A1	20010430 (9)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MCHALE & SLAVIN, 4440 PGA BLVD, SUITE 402, PALM BEACH GARDENS, FL, 33410
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 700
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
TI Biopolymer **marker** indicative of disease state having a molecular weight of 1777 daltons
AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 43 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2002:206130 USPATFULL
TITLE: Methods and compositions for perioperative genomic profiling
INVENTOR(S): Hogan, Kirk, Madison, WI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002110823	A1	20020815
APPLICATION INFO.:	US 2001-976423	A1	20011012 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-613887, filed on 11 Jul 2000, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MEDLEN & CARROLL, LLP, 101 HOWARD STREET, SUITE 350, SAN FRANCISCO, CA, 94105
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 2232
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
TI Methods and compositions for perioperative genomic profiling
AB The present invention relates to methods for perioperative genomic screening of subjects, in particular to perioperative screening for **markers** indicative of responses to anesthesia and other perioperative or operative treatments and procedures. The present invention also provides compositions for use in screening methods. The methods and compositions of the present invention find use in tailoring a subject's medical or surgical treatment to reflect genetic information that predicts a subject's response to medications or techniques used in the procedure.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 44 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2002:191154 USPATFULL
TITLE: Diagnostic/therapeutic agents
INVENTOR(S): Klaveness, Jo, Oslo, NORWAY
Rongved, Pal, Oslo, NORWAY
Hogset, Anders, Oslo, NORWAY
Tolleshaug, Helge, Oslo, NORWAY
Cuthbertson, Alan, Oslo, NORWAY
Godal, Aslak, Oslo, NORWAY
Hoff, Lars, Oslo, NORWAY
Gogstad, Geir, Oslo, NORWAY
Bryn, Klaus, Oslo, NORWAY
Naevestad, Anne, Oslo, NORWAY
Lovhaug, Dagfinn, Oslo, NORWAY
Hellebust, Halldis, Oslo, NORWAY
Solbakken, Magne, Oslo, NORWAY
PATENT ASSIGNEE(S): Nycomed Imaging AS (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002102217	A1	20020801
	US 6680047	B2	20040120
APPLICATION INFO.:	US 2001-925715	A1	20010810 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1997-959206, filed on 28 Oct 1997, PATENTED

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1996-22366	19961028
	GB 1996-22369	19961028
	GB 1997-2195	19970204
	GB 1997-8265	19970424
	GB 1997-11837	19970606
	GB 1997-11839	19970606
	US 1997-49263P	19970607 (60)
	US 1997-49264P	19970606 (60)
	US 1997-49266P	19970607 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Richard E. Fichter, BACON & THOMAS, PLLC, Fourth Floor, 625 Slaters Lane, Alexandria, VA, 22314-1176
NUMBER OF CLAIMS: 38
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 5190
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
TI Diagnostic/therapeutic agents
AB Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 45 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2002:27111 USPATFULL
TITLE: Diagnostics and therapeutics for macular degeneration-related disorders
INVENTOR(S): Hageman, Gregory S., Coralville, IA, UNITED STATES

Mullins, Robert F., Coralville, IA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002015957	A1	20020207
APPLICATION INFO.:	US 2001-845745	A1	20010430 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-200698P	20000429 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
NUMBER OF CLAIMS: 37
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 3111
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
TI Diagnostics and therapeutics for macular degeneration-related disorders
AB The invention relates to methods for treating, preventing and diagnosing macular degeneration-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 46 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2002:276121 USPATFULL
TITLE: Use of procyanidins in the maintenance of vascular health and modulation of the inflammatory response
INVENTOR(S): Romanczyk, Jr., Leo J., Hackettstown, NJ, United States
Schmitz, Harold H., Branchburg, NJ, United States
PATENT ASSIGNEE(S): Mars Incorporated, McLean, VA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6469053	B1	20021022
APPLICATION INFO.:	US 2000-507717		20000218 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-459171, filed on 10 Dec 1999 Continuation-in-part of Ser. No. US 1997-831245, filed on 2 Apr 1997, now patented, Pat. No. US 6297273 Continuation-in-part of Ser. No. US 1996-631661, filed on 2 Apr 1996, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Solola, T. A.
LEGAL REPRESENTATIVE: Kelley, Margaret B., Chance, Clifford, Rogers & Wells
NUMBER OF CLAIMS: 32
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 54 Drawing Figure(s); 48 Drawing Page(s)
LINE COUNT: 2648
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
TI Use of procyanidins in the maintenance of vascular health and modulation of the inflammatory response
AB Cocoa extracts which include procyanidin monomers and their oligomers are useful in the modulation of inflammatory pathways, in the maintenance of the vascular health of a mammal and as an antibacterial treatment. The liquid or dry cocoa extracts can be included in foods, food supplements and pharmaceuticals for the inhibition of COX activity, the inhibition of LOX activity, the enhancement of nitric oxide production, the modulation of eicosanoids and endothelin, and the modulation of platelet activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 47 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2002:254207 USPATFULL
TITLE: Treatment of a α-galactosidase a deficiency
INVENTOR(S): Selden, Richard F, Wellesley, MA, United States
Borowski, Marianne, Winthrop, MA, United States
Kinoshita, Carol M., Bedford, MA, United States
Treco, Douglas A., Arlington, MA, United States
Williams, Melanie D., Natick, MA, United States
Schuetz, Thomas J., Framingham, MA, United States
Daniel, Peter F., Natick, MA, United States
PATENT ASSIGNEE(S): Transkaryotic Therapies, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6458574	B1	20021001
APPLICATION INFO.:	US 1999-266014		19990311 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1996-928881, filed on 12 Sep 1996, now patented, Pat. No. US 6083725
Continuation-in-part of Ser. No. WO 1997-US16603, filed on 12 Sep 1997

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-26041P	19960913 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Prouty, Rebecca E.
ASSISTANT EXAMINER: Hutson, Richard
LEGAL REPRESENTATIVE: Fish & Richardson PC
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT: 2880
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
TI Treatment of a α-galactosidase a deficiency
AB The invention provides highly purified α-Gal A, and various methods for purifying it; α-Gal A preparations with altered charge and methods for making those preparations; α-Gal A preparations that have an extended circulating half-life in a mammalian host, and methods for making same; and methods and dosages for administering an α-Gal A preparation to a subject.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 48 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2001:231041 USPATFULL
TITLE: Targeted diagnostic/therapeutic agents having more than one different vectors
INVENTOR(S): Klaveness, Jo, Olso, Norway
Rongved, P.ang.l, Olso, Norway
H.o slashed.gset, Anders, Olso, Norway
Tolleshaug, Helge, Olso, Norway
Cuthbertson, Alan, Olso, Norway
Hoff, Lars, Olso, Norway
Bryn, Klaus, Olso, Norway
Hellebust, Halldis, Olso, Norway
Solbakken, Magne, Olso, Norway
PATENT ASSIGNEE(S): Nycomed Imaging AS, Oslo, Norway (non-U.S. corporation)

	NUMBER	KIND	DATE

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6331289	B1	20011218	
APPLICATION INFO.:	US 1997-959206		19971028	(8)

PRIORITY INFORMATION:	NUMBER	DATE	
	GB 1996-22366	19961028	
	GB 1996-22369	19961028	
	GB 1997-2195	19970204	
	GB 1997-8265	19970424	
	GB 1997-11837	19970606	
	GB 1997-11839	19970606	
	US 1997-49263P	19970606	(60)
	US 1997-49266P	19970607	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Hartley, Michael G.
LEGAL REPRESENTATIVE: Bacon & Thomas
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 4091
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
TI Targeted diagnostic/therapeutic agents having more than one different vectors
AB Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 49 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2001:231038 USPATFULL
TITLE: Structurally determined cyclic metallo-constructs and applications
INVENTOR(S): Sharma, Shubh D., Plainsboro, NJ, United States
PATENT ASSIGNEE(S): Palatin Technologies, Inc., Princeton, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6331285	B1	20011218	
APPLICATION INFO.:	US 1999-464358		19991215	(9)

RELATED APPLN. INFO.: Division of Ser. No. US 1996-660697, filed on 5 Jun 1996, now patented, Pat. No. US 6027711
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Jones, Dameron L.
LEGAL REPRESENTATIVE: Slusher, Stephen A.Peacock, Myers & Adams
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Figure(s); 14 Drawing Page(s)
LINE COUNT: 4839
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
TI Structurally determined cyclic metallo-constructs and applications
AB A metallo-construct, which may be a peptide, is provided for use as a biological, therapeutic, diagnostic imaging, or radiotherapeutic agent, and for use in library or combinatorial chemistry methods. The construct has a conformationally constrained global secondary structure obtained upon complexing with a metal ion. The peptide constructs are of the general formula:

R.sub.1 --X--R.sub.2

where X is a plurality of amino acids and includes a complexing backbone for complexing metal ions, so that substantially all of the valences of the metal ion are satisfied upon complexation of the metal ion with X, resulting in a specific regional secondary structure forming a part of the global secondary structure; and where R.sub.1 and R.sub.2 each include from 0 to about 20 amino acids, the amino acids being selected so that upon complexing the metal ion with X at least a portion of either R.sub.1 or R.sub.2 or both have a structure forming the balance of the conformationally constrained global secondary structure. All or a portion of the global secondary structure, which may be sychnologic or rhegnylogic, may form a ligand or mimic a known biological-function domain. The construct has substantially higher affinity for its target upon labeling with a metal ion.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 50 OF 52 USPATFULL on STN

ACCESSION NUMBER:	2000:21206 USPATFULL
TITLE:	Structurally determined metallo-constructs and applications
INVENTOR(S):	Sharma, Shubh D., Albuquerque, NM, United States
PATENT ASSIGNEE(S):	RhoMed Incorporated, Edison, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6027711		20000222
APPLICATION INFO.:	US 1996-660697		19960605 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-476652, filed on 7 Jun 1995, now patented, Pat. No. US 5891418, issued on 6 Apr 1999		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Dees, Jose G.		
ASSISTANT EXAMINER:	Jones, Dameron		
LEGAL REPRESENTATIVE:	Slusher, Stephen A., Todaro, John C., Peacock, Deborah A.		
NUMBER OF CLAIMS:	38		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	20 Drawing Figure(s); 14 Drawing Page(s)		
LINE COUNT:	4915		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Structurally determined metallo-constructs and applications

AB A metallo-construct, which may be a peptide, is provided for use as a biological, therapeutic, diagnostic imaging, or radiotherapeutic agent, and for use in library or combinatorial chemistry methods. The construct has a conformationally constrained global secondary structure obtained upon complexing with a metal ion. The peptide constructs are of the general formula:

R.sub.1 --X--R.sub.2

where X is a plurality of amino acids and includes a complexing backbone for complexing metal ions, so that substantially all of the valences of the metal ion are satisfied upon complexation of the metal ion with X, resulting in a specific regional secondary structure forming a part of the global secondary structure; and where R.sub.1 and R.sub.2 each include from 0 to about 20 amino acids, the amino acids being selected so that upon complexing the metal ion with X at least a portion of either R.sub.1 or R.sub.2 or both have a structure forming the balance

of the conformationally constrained global secondary structure. All or a portion of the global secondary structure, which may be sychnologic or rhegnylogic, may form a ligand or mimic a known biological-function domain. The construct has substantially higher affinity for its target upon labeling with a metal ion.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 51 OF 52 USPATFULL on STN
ACCESSION NUMBER: 1998:42387 USPATFULL
TITLE: Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors
INVENTOR(S): Illig, Carl R., Phoenixville, PA, United States
Soll, Richard M., Lawrenceville, NJ, United States
Salvino, Joseph M., Schwenksville, PA, United States
Tomczuk, Bruce E., Collegeville, PA, United States
Lu, Tianbao, Exton, PA, United States
Subasinghe, Nalin L., West Chester, PA, United States
PATENT ASSIGNEE(S): 3-Dimensional Pharmaceuticals, Inc., Exton, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5741819		19980421	
APPLICATION INFO.:	US 1995-488196		19950607	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Owens, Amelia
LEGAL REPRESENTATIVE: Sterne, Kessler, Goldstein & Fox, P.L.L.C.
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
LINE COUNT: 1240
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
TI Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors
AB The present invention is directed to non-peptidic factor Xa inhibitors which are useful for the treatment of arterial and venous thrombotic occlusive disorders, inflammation, cancer, and neurodegenerative diseases. The factor Xa inhibitors provide compounds of structure: ##STR1## or pharmaceutically acceptable salts thereof; wherein

R.sup.1 is alkyl, substituted alkyl, cycloalkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl; R.sup.2 is one of hydrogen, alkyl, cycloalkyl or aryl; R.sup.3 is one of hydrogen, hydroxy or alkoxy; R.sup.4 is one of --NH.sub.2, phenyl or pyridyl, wherein said phenyl and said pyridyl are optionally substituted with one or two of halogen, hydroxy, hydroxyalkyl, alkoxy, amino, monoalkylamino, dialkylamino, aminoalkyl, monoalkylaminoalkyl and/or dialkylaminoalkyl; X is one of --CH.sub.2 -- or --C(O)--; and n is from zero to eleven; provided that when R.sup.4 is --NH.sub.2, then R.sup.3 is hydrogen and n is other than zero; and also provided that when R.sup.3 is hydroxy or alkoxy, then R.sup.4 is other than --NH.sub.2, and n is other than zero.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 52 OF 52 USPATFULL on STN
ACCESSION NUMBER: 97:22821 USPATFULL
TITLE: Bis-arylsulfonylaminobenzamide derivatives and the use thereof as factor Xa inhibitors
INVENTOR(S): Tianbao, Lu, Exton, PA, United States
Soll, Richard M., Lawrenceville, NJ, United States
PATENT ASSIGNEE(S): 3-Dimensional Pharmaceuticals, Inc., Exton, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5612378		19970318	
APPLICATION INFO.:	US 1995-470579		19950606	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Dees, Jos e G.
ASSISTANT EXAMINER: Ledynh, Lily
LEGAL REPRESENTATIVE: Sterne, Kessler, Goldstein & Fox P.L.L.C.
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 730
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Bis-arylsulfonylaminobenzamide derivatives and the use thereof as factor Xa inhibitors

AB The present invention is directed to non-peptidic factor Xa inhibitors which are useful for the treatment of arterial and venous thrombotic occlusive disorders, inflammation, cancer, and neurodegenerative diseases. The factor Xa inhibitors provide compounds of structure: ##STR1## wherein each R.sup.1 is independently one of alkyl, substituted alkyl, cycloalkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl;

each R.sup.2 and R.sup.3 is independently one of hydrogen, alkyl, aryl or arylalkyl;

Y is a bond, or is one of --(CH.sub.2).sub.p --, cycloalkyl, aryl or C.sub.2-10 heterocycle; and

m, n and p are each independently 1 to 10.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> DIS HIST

(FILE 'HOME' ENTERED AT 12:22:08 ON 21 JAN 2005)

FILE 'REGISTRY' ENTERED AT 12:22:30 ON 21 JAN 2005
L1 1029 S FIBRINOGEN

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 12:23:04 ON 21 JAN 2005

SEA FIBRINOGEN	
2029	FILE ADISCTI
138	FILE ADISINSIGHT
268	FILE ADISNEWS
502	FILE AGRICOLA
161	FILE ANABSTR
57	FILE ANTE
4	FILE AQUALINE
105	FILE AQUASCI
450	FILE BIOBUSINESS
118	FILE BIOCOMMERCE
515	FILE BIOENG
31334	FILE BIOSIS
576	FILE BIOTECHABS
576	FILE BIOTECHDS
6481	FILE BIOTECHNO

```
  2010   FILE CABA
  3587   FILE CANCERLIT
 30223   FILE CAPLUS
   115   FILE CEABA-VTB
     5   FILE CEN
    92   FILE CIN
   695   FILE CONFSCI
    11   FILE CROPU
  1921   FILE DDFB
  5797   FILE DDFU
  5877   FILE DGENE
   719   FILE DISSABS
  1921   FILE DRUGB
    99   FILE DRUGMONOG2
  8235   FILE DRUGU
   194   FILE EMBAL
 34408   FILE EMBASE
  5465   FILE ESBIOBASE
   305   FILE FEDRIP
   164   FILE FROSTI
   134   FILE FSTA
  4405   FILE GENBANK
    44   FILE HEALSAFE
  2002   FILE IFIPAT
    48   FILE IMSDRUGNEWS
    58   FILE IMSPRODUCT
    61   FILE IMSRESEARCH
  3834   FILE JICST-EPLUS
     3   FILE KOSMET
  2542   FILE LIFESCI
    17   FILE MEDICONF
 37491   FILE MEDLINE
   164   FILE NIOSHTIC
   354   FILE NTIS
     4   FILE NUTRACEUT
    15   FILE OCEAN
  9706   FILE PASCAL
   281   FILE PHAR
    41   FILE PHARMAML
     1   FILE PHIC
   279   FILE PHIN
   677   FILE PROMT
  1752   FILE PROUSDDR
     1   FILE PS
     2   FILE RDISCLOSURE
 22169   FILE SCISEARCH
    17   FILE SYNTHLINE
 12419   FILE TOXCENTER
 11170   FILE USPATFULL
   755   FILE USPAT2
    27   FILE VETB
   174   FILE VETU
     3   FILE WATER
  2425   FILE WPIDS
    18   FILE WPIFV
  2425   FILE WPINDEX
   408   FILE IPA
    86   FILE NAPRALERT
   573   FILE NLDB
L2          QUE FIBRINOGEN
            ---------

FILE 'MEDLINE, EMBASE, BIOSIS, CAPLUS, SCISEARCH, TOXCENTER, USPATFULL,
```

```
     PASCAL, DRUGU, BIOTECHNO' ENTERED AT 12:25:57 ON 21 JAN 2005
L3        203636 S FIBRINOGEN
L4        473386 S MYOCARDIAL INFARCTION
L5        473386 S MYOCARDIAL (W) INFARCTION
L6          2525 S (MARKER OR (BIOMARKER)) AND L3 AND L5
L7          1897 DUP REM L6 (628 DUPLICATES REMOVED)
L8           670 S JACKOWSKI,G?/AU
L9           237 S THATCHER,B?/AU
L10        19338 S MARSHALL,J?/AU
L11           90 S YANTHA,J?/AU
L12           87 S VREES,T?/AU
L13        19980 S L8 OR L9 OR L10 OR L11 OR L12
L14         9671 DUP REM L13 (10309 DUPLICATES REMOVED)
L15         1889 S L7 NOT L14
L16            8 S L7 AND L14
L17        37915 S MALDI
L18           55 S L17 AND L7
L19           52 S L18 NOT L14
L20           52 DUP REM L19 (0 DUPLICATES REMOVED)

=>

---Logging off of STN---


=>
Executing the logoff script...


=> LOG Y

COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               103.52     111.71

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                                -2.92      -2.92

STN INTERNATIONAL LOGOFF AT 12:45:08 ON 21 JAN 2005
```